Next Article in Journal
Channel-Forming Bacterial Toxins in Biosensing and Macromolecule Delivery
Next Article in Special Issue
Engineering Venom’s Toxin-Neutralizing Antibody Fragments and Its Therapeutic Potential
Previous Article in Journal
The Correlation of the Presence and Expression Levels of cry Genes with the Insecticidal Activities against Plutella xylostella for Bacillus thuringiensis Strains
Previous Article in Special Issue
Diagnosis of Snakebite and the Importance of Immunological Tests in Venom Research
Open AccessArticle

Immunological Cross-Reactivity and Neutralisation of European Viper Venoms with the Monospecific Vipera berus Antivenom ViperaTAb

1
MicroPharm Limited, Station Road Industrial Estate, Newcastle Emlyn, Carmarthenshire SA38 9BY, UK
2
Alistair Reid Venom Research Unit, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK
*
Author to whom correspondence should be addressed.
Toxins 2014, 6(8), 2471-2482; https://doi.org/10.3390/toxins6082471
Received: 12 June 2014 / Revised: 13 August 2014 / Accepted: 13 August 2014 / Published: 19 August 2014
(This article belongs to the Special Issue Antivenom and Venom Therapeutics)
Medically important cases of snakebite in Europe are predominately caused by European vipers of the genus Vipera. The mainstay of snakebite therapy is polyclonal antibody therapy, referred to as antivenom. Here we investigate the capability of the monospecific V. berus antivenom, ViperaTAb®, to cross-react with, and neutralise lethality induced by, a variety of European vipers. Using ELISA and immunoblotting, we find that ViperaTAb® antibodies recognise and bind to the majority of toxic components found in the venoms of the Vipera species tested at comparably high levels to those observed with V. berus. Using in vivo pre-clinical efficacy studies, we demonstrate that ViperaTAb® effectively neutralises lethality induced by V. berus, V. aspis, V. ammodytes and V. latastei venoms and at much higher levels than those outlined by regulatory pharmacopoeial guidelines. Notably, venom neutralisation was found to be superior to (V. berus, V. aspis and V. latastei), or as equally effective as (V. ammodytes), the monospecific V. ammodytes “Zagreb antivenom”, which has long been successfully used for treating European snake envenomings. This study suggests that ViperaTAb® may be a valuable therapeutic product for treating snakebite by a variety of European vipers found throughout the continent. View Full-Text
Keywords: antivenom; snake; snakebite; Viperidae; European viper; antibodies antivenom; snake; snakebite; Viperidae; European viper; antibodies
Show Figures

Figure 1

MDPI and ACS Style

Casewell, N.R.; Al-Abdulla, I.; Smith, D.; Coxon, R.; Landon, J. Immunological Cross-Reactivity and Neutralisation of European Viper Venoms with the Monospecific Vipera berus Antivenom ViperaTAb. Toxins 2014, 6, 2471-2482. https://doi.org/10.3390/toxins6082471

AMA Style

Casewell NR, Al-Abdulla I, Smith D, Coxon R, Landon J. Immunological Cross-Reactivity and Neutralisation of European Viper Venoms with the Monospecific Vipera berus Antivenom ViperaTAb. Toxins. 2014; 6(8):2471-2482. https://doi.org/10.3390/toxins6082471

Chicago/Turabian Style

Casewell, Nicholas R.; Al-Abdulla, Ibrahim; Smith, David; Coxon, Ruth; Landon, John. 2014. "Immunological Cross-Reactivity and Neutralisation of European Viper Venoms with the Monospecific Vipera berus Antivenom ViperaTAb" Toxins 6, no. 8: 2471-2482. https://doi.org/10.3390/toxins6082471

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Search more from Scilit
 
Search
Back to TopTop